Pfizer leans on COVID products to top estimates
By Bhanvi Satija and Raghav Mahobe (Reuters) – Pfizer Inc on Tuesday reported higher-than-expected first-quarter revenue and profit, buoyed by demand for its COVID-19 products, and reaffirmed its 2023 earnings forecast as it banks on newer drugs to contribute to growth later this year. The company has said it expects 2023 to be a low…